Yukon Metals Corp press release

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MP, TASK and AKBA

2022-03-29

CSE - Canadian National Stock Exchange · Gold · Copper · Molybdenum · Silver · Lead · Zinc · Barium · Cadmium · Tin · Antimony · Arsenic · Cobalt · Nickel · Iron · Selenium · Tellurium · Scandium · Bismuth · Platinum · Lanthanum · Yttrium · Rare Earth Elements · Canada

NEW YORK, NY / ACCESSWIRE / March 29, 2022 /The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

MP Materials Corp. f/k/a Fortress Value Acquisition Corp. (NYSE:MP) _Class Period:_May 1, 2020 - February 2, 2022 _Lead Plaintiff Deadline:_April 25, 2022

The MP lawsuit alleges MP Materials Corp. f/k/a Fortress Value Acquisition Corp. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in MP: https://www.kleinstocklaw.com/pslra-1/mp-materials-corp-f-k-a-fortress-value-acquisition-corp-loss-submission-form?id=25305&from=1

Taskus, Inc. (NASDAQ:TASK) _Class Period:_June 11, 2021 - January 19, 2022 _Lead Plaintiff Deadline:_April 25, 2022

During the class period, Taskus, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) TaskUs was experiencing severe financial strain and business challenges, particularly with its most important customer, Facebook; (2) the Content Security market was smaller than defendants represented and defendants' representations were based on outdated market data; (3) TaskUs improperly recognized revenue from certain key contracts; (4) defendants overstated the size of TaskUs' workforce as well as employee retention rates, and understated attrition rates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in TASK: https://www.kleinstocklaw.com/pslra-1/taskus-inc-loss-submission-form?id=25305&from=1

Akebia Therapeutics, Inc. (NASDAQ:AKBA) _Class Period:_June 28, 2018 - September 2, 2020 _Lead Plaintiff Deadline:_May 13, 2022

The complaint alleges Akebia Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of a Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in AKBA: https://www.kleinstocklaw.com/pslra-1/akebia-therapeutics-inc-loss-submission-form?id=25305&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: J. Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com: https://www.accesswire.com/695144/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-MP-TASK-and-AKBA